1,938 reports of this reaction
6.3% of all BENDAMUSTINE HCL reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for BENDAMUSTINE HCL, manufactured by Meitheal Pharmaceuticals Inc.. There are 1,938 FDA adverse event reports linking BENDAMUSTINE HCL to OFF LABEL USE. This represents approximately 6.3% of all 30,914 adverse event reports for this drug.
Patients taking BENDAMUSTINE HCL who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among BENDAMUSTINE HCL users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for BENDAMUSTINE HCL:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,938 FDA reports for BENDAMUSTINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 6.3% of all adverse event reports for BENDAMUSTINE HCL, making it one of the most commonly reported side effect.
If you experience off label use while taking BENDAMUSTINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.